Answer
Rifampicin should be avoided where possible during pirtobrutinib treatment because strong CYP3A induction reduced pirtobrutinib AUC by 71% and Cmax by 42%, although this reduction in exposure is not expected to be clinically meaningful.
Sources for this answer
- Jaypirca 50mg, 100mg film-coated tabletsEli Lilly and Company Limited · emc · SmPC §4.5 Interaction with other medicinal products · Version 4Document updated
Sources checked